Genmab A/S
GMAB30.900USD
-0.070-0.23%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
19.02B시가총액
13.07P/E TTM
자세한 내용은 Genmab A/S 회사
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S 정보
종목 코드 GMAB
회사 이름Genmab A/S
상장일Oct 01, 2000
CEOVan De Winkel (Jan G.J)
직원 수2682
유형Depository Receipt
회계 연도 종료Oct 01
주소Carl Jacobsens Vej 30
도시VALBY
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Denmark
우편 번호2500
전화4570202728
웹사이트https://www.genmab.com/
종목 코드 GMAB
상장일Oct 01, 2000
CEOVan De Winkel (Jan G.J)
Genmab A/S의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Royalties
841.00M
82.29%
Net product sales
104.00M
10.18%
Milestone payments
53.00M
5.19%
Collaboration revenue
17.00M
1.66%
Reimbursement income
7.00M
0.68%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Royalties
841.00M
82.29%
Net product sales
104.00M
10.18%
Milestone payments
53.00M
5.19%
Collaboration revenue
17.00M
1.66%
Reimbursement income
7.00M
0.68%
주식 보유 통계
마지막 업데이트: Sun, Feb 1
마지막 업데이트: Sun, Feb 1
주주
주주 유형
주주
주주
비율
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
기타
94.64%
주주
주주
비율
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
기타
94.64%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
4.95%
Investment Advisor
3.48%
Hedge Fund
1.96%
Research Firm
0.19%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.02%
Venture Capital
0.01%
기타
89.33%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
539
65.54M
10.64%
-9.83M
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Orbis Investment Management Ltd.
11.08M
1.8%
+3.16M
+39.87%
Sep 30, 2025
AllianceBernstein L.P.
10.95M
1.78%
+291.54K
+2.73%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.82M
0.62%
+3.82M
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
3.64M
0.59%
+188.76K
+5.46%
Sep 30, 2025
Harding Loevner LP
3.48M
0.57%
+561.05K
+19.19%
Sep 30, 2025
Two Sigma Investments, LP
2.82M
0.46%
-615.53K
-17.90%
Sep 30, 2025
Renaissance Technologies LLC
2.82M
0.46%
+54.79K
+1.98%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
0.42%
+101.63K
+4.06%
Sep 30, 2025
First Trust Advisors L.P.
1.69M
0.27%
-82.92K
-4.68%
Sep 30, 2025
Parametric Portfolio Associates LLC
1.58M
0.26%
+391.90K
+32.97%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
더 보기
Tema Oncology ETF
비율4.2%
First Trust NYSE Arca Biotechnology Index Fund
비율3.02%
WisdomTree BioRevolution Fund
비율1.31%
iShares Biotechnology ETF
비율1.15%
AB Disruptors ETF
비율0.69%
JPMorgan Healthcare Leaders ETF
비율0.28%
First Trust NASDAQ BuyWrite Income ETF
비율0.26%
ProShares Ultra Nasdaq Biotechnology
비율0.12%
Invesco Nasdaq Biotechnology ETF
비율0.12%
ActivePassive International Equity ETF
비율0.12%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
